Advances in Biomarker-Guided Cancer Immunotherapy: Experts Discuss Clinical Utility and Future Directions

In this activity with downloadable slides review expert discussion on the optimal use of biomarker testing in multiple tumor types and treatment settings to select appropriate patients for treatment with immune checkpoint inhibitors.

Share

Program Content

Activities

MSI/MMR and TMB
Predictors of Response to Immune Checkpoint Inhibitors: MSI/MMR and TMB
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 29, 2019

Expires: March 27, 2020

PD-L1
Predictors of Response to Immune Checkpoint Inhibitors: PD-L1
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 29, 2019

Expires: March 27, 2020

Immune-Biomarker Diagnostics
Implementing Immune-Biomarker Diagnostics
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 29, 2019

Expires: March 27, 2020

Overview
Immune Checkpoint Inhibitors in Cancer Treatment: Overview
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 29, 2019

Expires: March 27, 2020

Future Directions in Immunotherapy Biomarkers
Future Directions in Cancer Immunotherapy Biomarker Development
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 29, 2019

Expires: March 27, 2020

Faculty

cover img faculity

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Jason N. Rosenbaum, MD

Assistant Professor
Department of Pathology and Laboratory Medicine
University of Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

cover img faculity

David R. Spigel, MD

Chief Scientific Officer
Director,
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Foundation Medicine